Clinical Pipeline

In view of the exceptional safety found in the Phase 2B for AK, the Company was allowed to enter directly into a Phase 2 for CTCL. The Phase 2 was initiated in

VDA-1102 Ointment VDA-1102 ointment is being developed under an IND from the FDA as a topical treatment for a variety of skin cancers. It has completed a rando

VDA-1275 is a potent small molecule new chemical entity (NCE) with novel mechanism of action that selectively modulates VDAC/HK2 interaction. It is highly poten

VDA-1102 is an anti-neoplastic agent that utilizes a novel mechanism of action involving selective modulation of VDAC/HK2, a molecular system that is unique to

VDA-1102 ointment is the First in a New Class of drugs that selectively targets malignant cutaneous cells with minimal effects on surrounding healthy skin. VDA-

Vidac Pharma is advancing a first-in-class portfolio in dermatology and oncology based on modulation of cancer cell metabolism. The Company’s programs span late